PTPN11 and ovarian carcinoma: Cells treated with cisplatin displayed enrichment in the WNT/β-catenin pathway and SHP2 signaling (Fig. 1A-B), a phenotype that is maintained in cisplatin-treated ovarian cancer patients (Fig. 1C).